Paying users zone. Data is covered by hidden.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal
Verified by Visa MasterCard SecureCode American Express SafeKey
Microsoft Excel LibreOffice Calc

Biogen Inc. (BIIB)


Statement of Cash Flows

Difficulty: Beginner

The cash flow statement provides information about a company’s cash receipts and cash payments during an accounting period, showing how these cash flaws link the ending cash balance to the beginning balance shown on the company’s statement of financial position.

The cash flow statement consists of three parts: cash flows provided by (used in) operating activities, cash flows provided by (used in) investing activities, and cash flows provided by (used in) financing activities.

Biogen Inc., Consolidated Statement of Cash Flows

USD $ in thousands

Microsoft Excel LibreOffice Calc
12 months ended Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Net income hidden hidden hidden hidden hidden
Depreciation, amortization and impairments hidden hidden hidden hidden hidden
Acquired in-process research and development hidden hidden hidden hidden hidden
Share-based compensation hidden hidden hidden hidden hidden
Deferred income taxes hidden hidden hidden hidden hidden
Contingent consideration hidden hidden hidden hidden hidden
Other hidden hidden hidden hidden hidden
Accounts receivable hidden hidden hidden hidden hidden
Due from anti-CD20 therapeutic programs hidden hidden hidden hidden hidden
Inventory hidden hidden hidden hidden hidden
Other assets hidden hidden hidden hidden hidden
Accrued expenses and other current liabilities hidden hidden hidden hidden hidden
Income tax assets and liabilities hidden hidden hidden hidden hidden
Other liabilities hidden hidden hidden hidden hidden
Changes in operating assets and liabilities, net hidden hidden hidden hidden hidden
Adjustments to reconcile net income to net cash flows from operating activities hidden hidden hidden hidden hidden
Net cash flows provided by operating activities hidden hidden hidden hidden hidden
Proceeds from sales and maturities of marketable securities hidden hidden hidden hidden hidden
Purchases of marketable securities hidden hidden hidden hidden hidden
Contingent consideration related to Fumapharm AG acquisition hidden hidden hidden hidden hidden
Acquired in-process research and development hidden hidden hidden hidden hidden
Acquisitions of businesses, net of cash acquired hidden hidden hidden hidden hidden
Purchases of property, plant and equipment hidden hidden hidden hidden hidden
Acquisitions of intangible assets hidden hidden hidden hidden hidden
Purchase of Ionis Pharmaceuticals, Inc. stock hidden hidden hidden hidden hidden
Investment in Samsung Bioepis hidden hidden hidden hidden hidden
Other hidden hidden hidden hidden hidden
Net cash flows used in investing activities hidden hidden hidden hidden hidden
Purchase of treasury stock hidden hidden hidden hidden hidden
Proceeds from (payments related to) issuance of stock for share-based compensation arrangements, net hidden hidden hidden hidden hidden
Net distribution to noncontrolling interest hidden hidden hidden hidden hidden
Proceeds from borrowings hidden hidden hidden hidden hidden
Repayments of borrowings hidden hidden hidden hidden hidden
Net cash contribution to Bioverativ, Inc. hidden hidden hidden hidden hidden
Excess tax benefit from share-based compensation hidden hidden hidden hidden hidden
Contingent consideration payments hidden hidden hidden hidden hidden
Other hidden hidden hidden hidden hidden
Net cash flows provided by (used in) financing activities hidden hidden hidden hidden hidden
Effect of exchange rate changes on cash and cash equivalents hidden hidden hidden hidden hidden
Net increase (decrease) in cash and cash equivalents hidden hidden hidden hidden hidden
Cash and cash equivalents, beginning of the year hidden hidden hidden hidden hidden
Cash and cash equivalents, end of the year hidden hidden hidden hidden hidden

Based on: 10-K (filing date: 2019-02-06), 10-K (filing date: 2018-02-01), 10-K (filing date: 2017-02-02), 10-K (filing date: 2016-02-03), 10-K (filing date: 2015-02-04).

Item Description The company
Net cash flows provided by operating activities Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. Biogen Inc.’s net cash flows provided by operating activities increased from 2016 to 2017 and from 2017 to 2018.
Net cash flows used in investing activities Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. Biogen Inc.’s net cash flows used in investing activities declined from 2016 to 2017 but then increased from 2017 to 2018 exceeding 2016 level.
Net cash flows provided by (used in) financing activities Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. Biogen Inc.’s net cash flows provided by (used in) financing activities declined from 2016 to 2017 and from 2017 to 2018.